Guideline Recommendations on Saw Palmetto for Benign Prostatic Hyperplasia

Guideline Position on Saw Palmetto

The American Urological Association (AUA) 2003 BPH guideline states that phytotherapeutic agents, including saw palmetto, cannot be recommended for treatment of BPH because the evidence is insufficient. 2
The AUA guideline panel concluded that there is insufficient evidence from well‑controlled trials to support saw palmetto as a treatment option, based on data reviewed through 2000. 1, 3

Saw palmetto may contain phytoestrogenic compounds that could theoretically affect serum PSA levels, but the exact composition of these supplements and their specific effects remain poorly characterized. (Evidence level: low/uncertain) 4, 5 – National Comprehensive Cancer Network (NCCN)
More than 20 % of men use herbal supplements such as saw palmetto for lower urinary tract symptoms, yet the lack of product standardization and robust quality evidence precludes a clinical recommendation. (Evidence level: low) 4, 5 – NCCN

Alpha‑blockers (e.g., alfuzosin, doxazosin, tamsulosin, terazosin) are recommended as first‑line medical therapy for men with bothersome moderate‑to‑severe BPH symptoms, providing rapid symptom relief within 2–4 weeks irrespective of prostate size. (Evidence level: strong) 6
For patients with mild or non‑bothersome symptoms, a watchful‑waiting approach is the standard management strategy. (Evidence level: strong) 6
In men with prostate volume > 30 cc and moderate‑to‑severe symptoms, combination therapy with an alpha‑blocker plus a 5‑alpha‑reductase inhibitor is advised. (Evidence level: strong) 6
Alpha‑blockers work by relaxing prostatic smooth muscle, thereby reducing the dynamic component of bladder outlet obstruction. (Evidence level: strong) 6

Patients should be informed that saw palmetto is not a guideline‑recommended treatment for BPH, and that evidence‑based therapies such as alpha‑blockers and 5‑alpha‑reductase inhibitors are available. (Evidence level: strong) 7, 6